- Record: found
- Abstract: not found
- Article: not found
Safety of reRT with SBRT plus concurrent and adjuvant pembrolizumab in patients with recurrent or new second primary head and neck squamous cell cancer in a previously irradiated field: RTOG 3507 Foundation (KEYSTROKE)
Read this article at
ScienceOpenPublisher
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.